Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 28;61(14):e202114722.
doi: 10.1002/anie.202114722. Epub 2022 Feb 3.

The Chemistry of Organic Contrast Agents in the NIR-II Window

Affiliations
Review

The Chemistry of Organic Contrast Agents in the NIR-II Window

Jing Mu et al. Angew Chem Int Ed Engl. .

Abstract

Optical imaging, especially fluorescence and photoacoustic imaging, is a non-invasive imaging approach with high spatial and temporal resolution and high sensitivity, compared to positron emission tomography (PET) or magnetic resonance imaging (MRI). Due to the merits of imaging using the second near-infrared (NIR-II) window, like deeper penetration depth, high signal-to-noise ratio, high resolution, and low tissue damage, researchers have devoted great effort to developing contrast agents with NIR-II absorption or emission. In this Review, we summarize recently developed organic luminescent and photoacoustic materials, ranging from small molecules to conjugated polymers. Then, we systematically introduce engineering strategies and describe the imaging performance classified by the skeleton cores. Finally, we elucidate the challenges and prospects of these NIR-II organic dyes for potential clinical applications. We expect our summary can inspire researchers to expand the spectrum of NIR-II contrast agents for diverse bioapplications.

Keywords: fluorescence imaging; organic fluorophores; photoacoustic imaging; second near-infrared (NIR-II).

PubMed Disclaimer

References

    1. R. L. Siegel, K. D. Miller, H. E. Fuchs, A. Jemal, CA-Cancer J. Clin. 2021, 71, 7-33.
    1. None
    1. I. I. Wistuba, J. G. Gelovani, J. J. Jacoby, S. E. Davis, R. S. Herbst, Nat. Rev. Clin. Oncol. 2011, 8, 135-141;
    1. J. K. Willmann, N. Van Bruggen, L. M. Dinkelborg, S. S. Gambhir, Nat. Rev. Drug Discovery 2008, 7, 591-607.
    1. None

Publication types

LinkOut - more resources